GLMD

+ Watchlist + Portfolio

Galmed Pharmaceuticals Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.77
52-Week Range: $3.29 – $13.20
Market Cap: $4.75M
P/E (TTM): —
EPS (TTM): -16.48
Dividend Yield: —

Advanced Metrics

Price/Book: 2.16
PEG Ratio: —
Return on Equity: -72.12%
Return on Assets: -33.46%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 7.71
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-4.99M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-11.77M

GLMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$12.99M	$3.57M	$2.98M	$4.87M
Selling, General & Admin	$4.66M	$3.92M	$3.30M	$3.64M
Operating Expenses	$17.65M	$7.49M	$6.28M	$8.51M
Operating Income	-$17.65M	-$7.49M	-$6.28M	-$8.51M
EBITDA	-$17.62M	-$7.46M	-$6.20M	-$8.51M
Pretax Income	-$17.87M	-$6.91M	-$7.52M	-$10.31M
Net Income	-$17.87M	-$6.91M	-$7.52M	-$10.31M
Diluted EPS	-127.80	-30.00	-8.08	-2.39
Diluted Shares	139682	230795	930822	4.31M

GLMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.02M	$2.86M	$4.65M	$3.98M
Receivables	$157.00K	$165.00K	$209.00K	$80.00K
Current Assets	$14.72M	$13.24M	$16.12M	$18.63M
Total Assets	$16.56M	$16.63M	$18.50M	$18.63M
Current Liabilities	$3.09M	$2.75M	$2.17M	$2.85M
Total Debt	$215.00K	$41.00K	$0.00	—
Total Liabilities	$3.14M	$2.75M	$2.17M	$2.85M
Retained Earnings	-$186.04M	-$192.95M	-$200.47M	-$210.78M
Shareholders' Equity	$13.42M	$13.88M	$16.33M	$15.78M
Working Capital	$11.63M	$10.49M	$13.95M	$15.78M

GLMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.50M	-$6.14M	-$5.88M	-$6.32M
Capital Expenditure	-$4.00K	—	—	—
Free Cash Flow	-$18.50M	-$6.14M	-$5.88M	-$6.32M
Depreciation & Amortisation	$35.00K	$31.00K	$83.00K	$0.00
Stock-Based Compensation	$1.30M	$892.00K	$531.00K	$546.00K
Investing Cash Flow	$17.56M	$800.00K	-$1.11M	-$3.38M
Financing Cash Flow	$70.00K	$6.18M	$8.79M	$9.03M
Net Change in Cash	-$868.00K	$848.00K	$1.79M	-$664.00K

GLMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$634.00K	$1.06M	$1.09M	$2.10M	$1.36M
Selling, General & Admin	$630.00K	$1.05M	$1.01M	$946.00K	$684.00K
Operating Expenses	$1.26M	$2.11M	$2.10M	$3.04M	$2.04M
Operating Income	-$1.26M	-$2.11M	-$2.10M	-$3.04M	-$2.04M
EBITDA	-$1.26M	-$2.11M	-$2.10M	-$3.04M	-$2.04M
Pretax Income	-$1.10M	-$2.50M	-$1.89M	-$4.82M	-$1.91M
Net Income	-$1.10M	-$2.50M	-$1.89M	-$4.82M	-$1.91M
Diluted EPS	-0.62	-0.63	-0.33	—	-0.29
Diluted Shares	1.80M	3.95M	5.46M	—	6.59M

GLMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.77M	$4.96M	$3.31M	$3.98M	$1.60M
Receivables	$447.00K	$433.00K	$549.00K	$80.00K	$451.00K
Current Assets	$16.30M	$21.08M	$19.72M	$18.63M	$16.03M
Total Assets	$18.68M	$22.94M	$21.58M	$18.63M	$16.03M
Current Liabilities	$1.81M	$2.42M	$2.47M	$2.85M	$2.08M
Total Liabilities	$1.81M	$2.42M	$2.47M	$2.85M	$2.08M
Retained Earnings	-$201.57M	-$204.07M	-$205.96M	-$210.78M	-$212.69M
Shareholders' Equity	$16.88M	$20.52M	$19.11M	$15.78M	$13.95M
Working Capital	$14.49M	$18.66M	$17.25M	$15.78M	$13.95M

GLMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.17M	-$1.27M	-$1.94M	-$1.95M	-$2.54M
Free Cash Flow	-$1.17M	-$1.27M	-$1.94M	-$1.95M	-$2.54M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$0.00	—
Stock-Based Compensation	$101.00K	$100.00K	$105.00K	$240.00K	$156.00K
Investing Cash Flow	-$231.00K	-$4.57M	-$3.00K	$1.43M	$152.00K
Financing Cash Flow	$1.51M	$6.04M	$289.00K	$1.19M	$0.00
Net Change in Cash	$116.00K	$198.00K	-$1.65M	$671.00K	-$2.38M

Market Snapshot

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for liver, metabolic, and inflammatory diseases. The company's lead product candidate targets non-alcoholic steatohepatitis (NASH) and other chronic liver conditions affecting millions of patients worldwide. Galmed conducts clinical trials to evaluate the safety and efficacy of its drug candidates, seeking regulatory approval for commercialization. As a development-stage company, Galmed does not yet generate product revenue and relies on financing activities to fund its research and clinical programs.